Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasm Metastasis 40Lung Neoplasms 32Multiple Myeloma 24Leukemia, Myeloid, Acute 24Colorectal Neoplasms 23Carcinoma, Non-Small-Cell Lung 20Lymphoma 19Breast Neoplasms 19Urinary Bladder Neoplasms 17Pancreatic Neoplasms 16Prostatic Neoplasms 15Ovarian Neoplasms 15Triple Negative Breast Neoplasms 14Melanoma 14Carcinoma, Renal Cell 12Sarcoma 11Glioma 11Carcinoma, Transitional Cell 11Mouth Neoplasms 10Fallopian Tube Neoplasms 10Endometrial Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Neuroblastoma 9Laryngeal Neoplasms 9Glioblastoma 9Carcinoma 9Burkitt Lymphoma 9Stomach Neoplasms 8Oropharyngeal Neoplasms 8Osteosarcoma 7

Interventions

ipatasertib 1entinostat 1Specimen Handling 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Magnetic Resonance Spectroscopy 1Hysterectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Specimen Handling × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡